The stock price of Protalix BioTherapeutics Inc (AMEX: PLX) has jumped by 885692 compared to previous close of 1.35. Despite this, the company has seen a gain of 6.99% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-09 that Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Mike Moyer – Investor Relations Dror Bashan – President and Chief Executive Officer Eyal Rubin – Senior Vice President and Chief Financial Officer Conference Call Participants John Vandermosten – Zacks Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2025 Financial and Business Results Conference Call. As a reminder, this conference is being recorded.
Is It Worth Investing in Protalix BioTherapeutics Inc (AMEX: PLX) Right Now?
Protalix BioTherapeutics Inc (AMEX: PLX) has a higher price-to-earnings ratio of 36.43x compared to its average ratio, The 36-month beta value for PLX is at -0.23. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PLX is 73.81M, and currently, shorts hold a 1.30% of that float. The average trading volume for PLX on June 25, 2025 was 901.48K shares.
PLX’s Market Performance
PLX stock saw a decrease of 6.99% in the past week, with a monthly decline of -7.27% and a quarterly a decrease of -41.15%. The volatility ratio for the week is 6.93%, and the volatility levels for the last 30 days are 4.02% for Protalix BioTherapeutics Inc (PLX). The simple moving average for the past 20 days is 0.76% for PLX’s stock, with a -18.16% simple moving average for the past 200 days.
Analysts’ Opinion of PLX
Many brokerage firms have already submitted their reports for PLX stocks, with H.C. Wainwright repeating the rating for PLX by listing it as a “Buy.” The predicted price for PLX in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on June 08, 2020 of the previous year 2020.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PLX reach a price target of $5, previously predicting the price at $4. The rating they have provided for PLX stocks is “Buy” according to the report published on April 17th, 2017.
Rodman & Renshaw gave a rating of “Buy” to PLX, setting the target price at $3.50 in the report published on April 04th of the previous year.
PLX Trading at -24.68% from the 50-Day Moving Average
After a stumble in the market that brought PLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.65% of loss for the given period.
Stock Fundamentals for PLX
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.5 for the gross margin
The net margin for Protalix BioTherapeutics Inc stands at 0.07. The total capital return value is set at 0.09. Equity return is now at value 10.42, with 4.77 for asset returns.
Based on Protalix BioTherapeutics Inc (PLX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.11. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is 6.83.
Currently, EBITDA for the company is 6.52 million with net debt to EBITDA at -1.99. When we switch over and look at the enterprise to sales, we see a ratio of 1.8. The receivables turnover for the company is 12.78for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.49.
Conclusion
In conclusion, Protalix BioTherapeutics Inc (PLX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
